Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Summary
-
- Relacorilant showed clinically significant and durable cardiometabolic improvements and was well-tolerated in patients with hypercortisolism treated for 6+ years
- Blood pressure continued to improve during the extension study
- Improvements in weight and glycemic measures were maintained
- Due to relacorilant’s specificity for the glucocorticoid receptor and its unique mechanism of action, the observed efficacy was seen:
- Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy
- Without increases in cortisol concentrations and relacorilant-induced hypokalemia
- Without reported cases of adrenal insufficiency
- Without independently confirmed QT prolongation
- Relacorilant showed clinically significant and durable cardiometabolic improvements and was well-tolerated in patients with hypercortisolism treated for 6+ years